Patrick Hensley discusses research led by Kim Toumazos and Spencer Bell analyzing patient-reported outcome incorporation in non-muscle-invasive bladder cancer trials. The Clinical ...
Umang Swami presents the OPTIMAS phase 2 randomized trial for metastatic hormone-sensitive prostate cancer evaluating treatment de-intensification. Patients receive relugolix plus ...
Sophie Merrick discusses patient-reported outcomes from RAMPART, evaluating adjuvant durvalumab plus tremelimumab versus observation in renal cell carcinoma. At week 16, patients ...
Dr. Watabe notes that in his home of Osaka, Japan, there is a new cyclotron (MP-30X, Sumitomo) dedicated to the production of ...
The 2026 PSMA & Beyond conference featured a challenges of radioligand therapy session and a presentation by Dr. Daniel Childs discussing long term marrow toxicity rates and risk factors. 177 ...
The 2026 PSMA and Beyond conference featured an approaches to combination therapies session and presentation by Dr. Lawrence ...
The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Wolfgang Fendler discussing the pro stance for the future of FAP. Fibroblast Activation ...
Whereas it may appear that Ac-PSMA has had a slower development trajectory compared to Lu-PSMA radioligand therapy, Dr. Eiber ...
The 2026 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. William Huang discussing the ...
Dr. Morris then discussed the PCWG4 Rule of 5 for defining radiographic progression free survival in the post-flare period. If there are <=5 new metastases, a confirmatory scan is performed, and if ...
The 2026 PSMA & Beyond conference featured a session on challenges of radioligand therapy and a presentation by Dr. Inès Camille Azrour discussing renal toxicity associated with PSMA targeted therapy.
The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Philipp Backhaus discussing the initial experience with APC3. The history of ACP3 goes back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results